Back to search

United Kingdom· GB-APID-42143411000001103

Sotyktu 6mg tablets

A deucravacitinib product containing deucravacitinib, registered in United Kingdom by Bristol-Myers Squibb Pharmaceuticals Ltd. The same ATC class is registered in 12 of our 19 countries.

ATC L04AF07

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedSotyktu 6mg tabletsATCL04AF07REGISTER NO.GB-APID-4214341100000…PACKS LISTED4CHECKEDSeptember 13, 2026

Where it is registered

Deucravacitinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AF07 (deucravacitinib), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 7 of them publish a price we can compare per daily dose

Deucravacitinib · ATC L04AF07

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deucravacitinib costs, country by country.

Normalised to the WHO defined daily dose (6 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Deucravacitinib · price per daily dose (6 mg)

USD · FX 28 Sept 2026

  • FR France$22.97
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Deucravacitinib
Manufacturer
Bristol-Myers Squibb Pharmaceuticals Ltd
Country
United Kingdom (GB)
ATC code
L04AF07
ATC class
Deucravacitinib
Defined daily dose
6 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 4

  • gtin
    05012712800125
  • gtin
    5012712800125
  • gtin
    5012712800132
  • gtin
    05012712800132

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Deucravacitinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deucravacitinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sotyktu
  • Liechtenstein · Sotyktu
  • Norway · Sotyktu

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dc30d339-6c62-47ce-9bfa-46c0692f0813
GET /v1/drugs/dc30d339-6c62-47ce-9bfa-46c0692f0813?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "42143411000001103",
  "desc": "Sotyktu 6mg tablets (Bristol-Myers Squibb Pharmaceuticals Ltd)",
  "form": "Oral tablet",
  "vpid": "42174811000001104",
  "source": "dmd",
  "vtm_id": "42174711000001107",
  "strength": "6 mg",
  "substance": "Deucravacitinib",
  "ingredient": "Deucravacitinib",
  "supplier_code": "3145301000001104"
}

See everything about deucravacitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.